ReviewACS infectious diseases2018
Tiny Things with Enormous Impact: Nanotechnology in the Fight Against Infectious Disease.
Review in ACS infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Innovative Strategies for Combating Multidrug-Resistant Tuberculosis: Advances in Drug Delivery Systems and Treatment.Microorganisms · 2025Review
- Nanomedicine in the Fight Against Multidrug-Resistant Infections: A Review on Emerging Strategies and Translational Prospects.International journal of nanomedicine · 2025Review
- Enhanced Antimalarial and Antisequestration Activity of Methoxybenzenesulfonate-Modified Biopolymers and Nanoparticles for Tackling Severe Malaria.ACS infectious diseases · 2024Article
- Advanced drug delivery and therapeutic strategies for tuberculosis treatment.Journal of nanobiotechnology · 2023Review
- Regulation ofPharmaceutics · 2023Review
- Nanotechnology approaches for global infectious diseases.Nature nanotechnology · 2021Review
- Liposomes-In-Hydrogel Delivery System Enhances the Potential of Resveratrol in Combating Vaginal Chlamydia Infection.Pharmaceutics · 2020Article
- How can nanotechnology help to combat COVID-19? Opportunities and urgent need.Journal of nanobiotechnology · 2020Review
- Characterization of Redox-Responsive LXR-Activating Nanoparticle Formulations in Primary Mouse Macrophages.Molecules (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Nanoparticles have exceptional properties that make them outstanding candidates for improving diagnostics and the treatment of infectious disease. Their small size, distinctive intrinsic properties, and ability to be decorated with a variety of complex functionalities make them uniquely capable of detection and targeting of certain diseases. Nanotechnology has the ability to increase the sensitivity of detection methods, the potency and ease of treatment, and the effectiveness of vaccinations. However, major challenges remain to their application in low-resource settings due in large part to the sensitivity of these particles to their local environment, a property that makes them both exceptional for detection and prone to complications or failure during synthesis and utilization. These challenges are likely to be solved only by continued and enhanced communication across scientific disciplines, for example, medical doctors and diagnosticians providing information about what is needed in new technologies. This information will enable materials scientists and engineers to rapidly address the corresponding technical challenges, such as the scalable and reproducible generation of nontoxic and stable, yet responsible nanoparticles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.